Omalizumab
Brand name: Xolair
Rank #160 of 500 drugs by total cost
$98.9M
Total Cost
30,451
Total Claims
$98.9M
Total Cost
1,159
Prescribers
$3,248
Cost per Claim
368
Beneficiaries
31,016
30-Day Fills
$85K
Avg Cost/Provider
26
Avg Claims/Provider
About Omalizumab
Omalizumab (sold as Xolair) was prescribed 30,451 times by 1,159 Medicare Part D providers in 2023, costing the program $98.9M. At $3,248 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 157 | Ubrogepant (Ubrelvy) | $100.6M | 75,781 |
| 158 | Darunavir/Cobicistat (Prezcobix) | $99.7M | 38,374 |
| 159 | Tocilizumab (Actemra) | $99.5M | 24,891 |
| 160 | Omalizumab (Xolair) | $98.9M | 30,451 |
| 161 | Brimonidine Tartrate (Alphagan P) | $98.8M | 988,570 |
| 162 | Dexlansoprazole (Dexlansoprazole Dr) | $98.7M | 275,116 |
| 163 | Interferon Beta-1a (Avonex) | $98.3M | 11,314 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology